Table 2. Cumulative incidence of toxicity.

	During G/D scheme		During mP6
Toxicity	All grades	Grades 3–4	All grades	Grades 3–4
Haematology
Anaemia	8	0	64	41
Absolute neutrophil count decreased	12	9	55	51
Platelet count decreased	7	4	57	52
Chemistry
ALT increase	9	4	10	2
AST increase	7	4	9	2
Hypoalbuminemia	0	0	1	0
Hypokalaemia	0	0	7	1
Hyponatremia	1	0	16	2
Gastrointestinal disorders
Diarrhoea	9	1	13	0
Constipation	5	0	22	1
Nausea	8	0	28	3
Vomiting	6	0	33	2
Mucositis	6	0	40	9
Dyspepsia	0	0	3	0
Enterocolitis	0	0	1	1
Infections
Febrile neutropenia	2	1	48	48
Urinary tract infection	2	1	2	1
Skin/subcutaneous infection	2	1	9	4
Upper airway infection	0	0	1	0
Chicken pox	1	0	1	1
Lip infection	1	1	2	0
Lung infection	2	1	3	2
Otitis media	0	0	1	0
Pharyngitis	0	0	1	1
Sepsis	0	0	2	2
Oral candidiasis	1	0	2	0
Skin tissue disorders
Rash	1	0	5	0
Palmar-plantar syndrome	0	0	2	0
Immune system disorders
Allergic reaction	4	0	0	0
General disorders
Oedema limbs	4	0	4	0
Pain	15	3	42	4
Vascular disorders
Phlebitis	0	0	3	0
Respiratory, thoracic and mediastinal disorders
Cough	3	0	5	0
Dyspnoea	1	0	2	0
Epistaxis	3	0	2	0
Respiratory failure	0	0	1	1
Injury, poisoning and procedural complications
Fracture	2	2	1	1
Neoplasms benign, malignant and unspecified
Leukaemia secondary to oncology chemotherapy	1	1	1	1
Renal and urinary disorders
Cystitis non infected	0	0	1	1

Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; G/D=Gemcitabine and Docetaxel.

National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

Toxicities of the G/D scheme refer to those reported both during the window cycles and maintenance.